BOHEMIA, N.Y., June 25, 2018 (LGS Foundation) – The LGS Foundation is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX® (cannabidiol / CBD) for the…
According to a story from uk.news.yahoo.com, when Billy Caldwell, age 12, and his mother returned from traveling to Canada, the Home Office initially confiscated a substance that had been the…
According to a story from Human Rights Watch, stories of preventable fatalities due to medical emergencies in immigrant detention centers in the U.S. have begun to emerge. In many cases,…
Avedro has announced that patients are now being enrolled in a Phase III trial of an epithelium-on (epi-on) corneal collagen cross-linking procedure designed as a treatment for patients who have…
According to a story from the Washington Post, the US Food and Drug Administration (FDA) has cleared the approval of Epidiolex®, a solution whose active ingredient is a refined version…
According to a story from BioPortfolio, the biotechnology company Vertex Pharamceuticals, Inc. recently announced that the long term use of its innovative cystic fibrosis treatment Orkambi will be covered in…
According to a story from GlobeNewsWire, the biopharmaceutical company Orphazyme A/S, which is committed to the development of treatments for patients that are living with rare diseases, has recently announced…
According to a story from Angelman Syndrome news, Angelman syndrome was recently given its own disease unique disease code: Q93.51. The new code will help make researching and tracking the…
According to medicalxpress.com, Hepatocellular carcinoma is the third leading cause of cancer deaths in the world. It is also the most common form of liver cancer. New research from a…
Arrowhead Pharmaceuticals, Inc. have announced that they have completed patient enrollment for a Phase 1 clinical trial investigating ARO-AAT, an investigational therapy for the treatment of a genetic liver disease…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
